Bioethics News

Pink Viagra sales tank

A few weeks ago “pink Viagra”, more properly known as Addyi, got a green light from the FDA. The drug purports to treat “hypoactive sexual desire disorder” in women. The day after the approval, Sprout Pharmaceuticals, a small company with the patent, was sold for US$1 billion in cash to Valeant Pharmaceuticals International. Valeant obviously thought it had a winner. 

It turns out that it has backed the wrong horse. In the first few weeks, only 227 prescriptions have been filled. “I thought there was going to be this huge onslaught,” the director of the Women’s Health Clinic at the Mayo Clinic told Bloomberg Business

Addyi has a lot of drawbacks; it has potentially deadly side effects, women can’t drink alcohol while using it; it costs US$780 a month; and it must be taken daily. But the biggest problem might be that Valeant believed Sprout’s canny public relations campaign which promoted sex as “a basic human right” and one of the FDA’s “priority areas of unmet medical need”. Perhaps women are more interested in commitment than a Viagra they can call their own. 

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.